Cargando…

放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析

BACKGROUND AND OBJECTIVE: Immunotherapy (IT) is recommended for the treatment of advanced non-small cell lung cancer (NSCLC), while brain radiotherapy (RT) is the mainstream treatment for patients with brain metastases (BM). This study aimed to investigate the efficacy and safety of combined use of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619347/
https://www.ncbi.nlm.nih.gov/pubmed/36285391
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.48
_version_ 1784821254805520384
collection PubMed
description BACKGROUND AND OBJECTIVE: Immunotherapy (IT) is recommended for the treatment of advanced non-small cell lung cancer (NSCLC), while brain radiotherapy (RT) is the mainstream treatment for patients with brain metastases (BM). This study aimed to investigate the efficacy and safety of combined use of RT and IT. METHODS: The date was limited to May 1, 2022, and literature searches were carried out in CNKI, Wanfang, PubMed, EMBASE and Cochrane databases. Heterogeneity was judged using the I(2) test and P value. Publication bias was assessed using a funnel plot. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analysis was performed using Stata 16.0 software. RESULTS: A total of 17 articles involving 2, 636 patients were included. In the comparison of RT+IT group and RT group, no significant difference was found in overall survival (OS) (HR=0.85, 95%CI: 0.52-1.38, I(2)=73.9%, P(heterogeneity)=0.001) and intracranial distance control (DBC) (HR=1.04, 95%CI: 0.55-1.05, I(2)=80.5%, P(heterogeneity) < 0.001), but the intracranial control (LC) in the RT+IT group was better than the RT group (HR=0.46, 95%CI: 0.22-0.94, I(2)=22.2%, P(heterogeneity)=0.276), and the risk of radiation necrosis/treatment-related imaging changes (RN/TRIC) was higher than RT (HR=1.72, 95%CI: 1.12-2.65, I(2)=40.2%, P(heterogeneity)=0.153). In the comparison between the RT+IT concurrent group and the sequential group, no significant difference was found in OS (HR=0.62, 95%CI: 0.27-1.43, I(2)=74.7%, P(heterogeneity)=0.003) and RN/TRIC (HR=1.72, 95%CI: 0.85-3.47, I(2)=0%, P(heterogeneity)=0.388) was different between the two groups. However, DBC in the concurrent treatment group was better than that in the sequential treatment group (HR=0.77, 95%CI: 0.62-0.96, I(2)=80.5%, P(heterogeneity) < 0.001). CONCLUSION: RT combined with IT does not improve the OS of NSCLC patients with BM, but also increases the risk of RN/TRIC. In addition, compared with sequential RT and IT, concurrent RT and IT improved the efficacy of DBC.
format Online
Article
Text
id pubmed-9619347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-96193472022-11-14 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Immunotherapy (IT) is recommended for the treatment of advanced non-small cell lung cancer (NSCLC), while brain radiotherapy (RT) is the mainstream treatment for patients with brain metastases (BM). This study aimed to investigate the efficacy and safety of combined use of RT and IT. METHODS: The date was limited to May 1, 2022, and literature searches were carried out in CNKI, Wanfang, PubMed, EMBASE and Cochrane databases. Heterogeneity was judged using the I(2) test and P value. Publication bias was assessed using a funnel plot. The quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analysis was performed using Stata 16.0 software. RESULTS: A total of 17 articles involving 2, 636 patients were included. In the comparison of RT+IT group and RT group, no significant difference was found in overall survival (OS) (HR=0.85, 95%CI: 0.52-1.38, I(2)=73.9%, P(heterogeneity)=0.001) and intracranial distance control (DBC) (HR=1.04, 95%CI: 0.55-1.05, I(2)=80.5%, P(heterogeneity) < 0.001), but the intracranial control (LC) in the RT+IT group was better than the RT group (HR=0.46, 95%CI: 0.22-0.94, I(2)=22.2%, P(heterogeneity)=0.276), and the risk of radiation necrosis/treatment-related imaging changes (RN/TRIC) was higher than RT (HR=1.72, 95%CI: 1.12-2.65, I(2)=40.2%, P(heterogeneity)=0.153). In the comparison between the RT+IT concurrent group and the sequential group, no significant difference was found in OS (HR=0.62, 95%CI: 0.27-1.43, I(2)=74.7%, P(heterogeneity)=0.003) and RN/TRIC (HR=1.72, 95%CI: 0.85-3.47, I(2)=0%, P(heterogeneity)=0.388) was different between the two groups. However, DBC in the concurrent treatment group was better than that in the sequential treatment group (HR=0.77, 95%CI: 0.62-0.96, I(2)=80.5%, P(heterogeneity) < 0.001). CONCLUSION: RT combined with IT does not improve the OS of NSCLC patients with BM, but also increases the risk of RN/TRIC. In addition, compared with sequential RT and IT, concurrent RT and IT improved the efficacy of DBC. 中国肺癌杂志编辑部 2022-10-20 /pmc/articles/PMC9619347/ /pubmed/36285391 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.48 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 临床研究
放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
title 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
title_full 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
title_fullStr 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
title_full_unstemmed 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
title_short 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
title_sort 放疗联合免疫治疗对肺癌脑转移的疗效和安全性的meta分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619347/
https://www.ncbi.nlm.nih.gov/pubmed/36285391
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.48
work_keys_str_mv AT fàngliáoliánhémiǎnyìzhìliáoduìfèiáinǎozhuǎnyídeliáoxiàohéānquánxìngdemetafēnxī
AT fàngliáoliánhémiǎnyìzhìliáoduìfèiáinǎozhuǎnyídeliáoxiàohéānquánxìngdemetafēnxī
AT fàngliáoliánhémiǎnyìzhìliáoduìfèiáinǎozhuǎnyídeliáoxiàohéānquánxìngdemetafēnxī